In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who ...

WGN’s Dina Bair has the latest on new medical information, including: Study: Mounjaro helped people achieve more weight loss ...

IT ONCE boasted over five million subscribers and saw one million of us stepping onto the scales every year. But Weight ...

Tirzepatide is a weight loss drug for adults with obesity or with overweight who also have weight-related medical problems, as Zepbound in the US and Mounjaro in some countries outside of the US ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

Weight loss drugs have been pitted against each other in a first of its kind head-to-head trial. Mounjaro and Wegovy were put ...

The findings come after reports of nasty side effects - including eye problems, infections and gastrointestinal disorders - ...

Natalie Strange, 36, from Manchester, was told by her doctor she was pre-diabetic and had a 'dangerous' level of high blood ...

A leading obesity doctor has said a new trial of weight loss drugs Mounjaro and Wegovy may lead advertisers to reconsider their prices.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...